Connor Clark & Lunn Investment Management Ltd. Buys 127,868 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 126.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 229,138 shares of the company’s stock after purchasing an additional 127,868 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.32% of Zentalis Pharmaceuticals worth $843,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. Values First Advisors Inc. boosted its position in Zentalis Pharmaceuticals by 5.4% during the second quarter. Values First Advisors Inc. now owns 74,925 shares of the company’s stock valued at $306,000 after purchasing an additional 3,859 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after acquiring an additional 5,333 shares in the last quarter. Carson Advisory Inc. boosted its holdings in Zentalis Pharmaceuticals by 55.8% in the third quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock worth $90,000 after acquiring an additional 8,800 shares in the last quarter. Anfield Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals in the second quarter worth about $40,000. Finally, Aigen Investment Management LP acquired a new stake in Zentalis Pharmaceuticals in the third quarter worth about $41,000.

Analyst Ratings Changes

Several brokerages have weighed in on ZNTL. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Guggenheim lowered their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. Oppenheimer reissued an “outperform” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Finally, Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective for the company in a research note on Monday, August 12th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

Zentalis Pharmaceuticals Trading Up 4.3 %

Shares of ZNTL stock opened at $3.63 on Thursday. The stock has a 50 day moving average of $3.40 and a 200 day moving average of $4.95. The stock has a market cap of $258.67 million, a P/E ratio of -1.46 and a beta of 1.74. Zentalis Pharmaceuticals, Inc. has a twelve month low of $2.66 and a twelve month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.36. On average, research analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.48 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.